Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gemtuzumab ozogamicin.

J K McGavin1, C M Spencer

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|August 21, 2001
PubMed
Summary
This summary is machine-generated.

Gemtuzumab ozogamicin offers a targeted therapy for acute myeloid leukemia (AML) by targeting CD33+ leukaemic cells. Clinical studies show it induces remission in a significant percentage of relapsed adult AML patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy.

CNS drugs·2016
Same author

Quetiapine : A Review of its Use in Schizophrenia.

CNS drugs·2016
Same author

The Yin and Yang of inflammation.

Current molecular medicine·2014
Same author

Lymphotoxin beta receptor signaling limits mucosal damage through driving IL-23 production by epithelial cells.

Mucosal immunology·2014
Same author

Lanoteplase.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Sdz asm 981.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • Gemtuzumab ozogamicin is an antibody-drug conjugate targeting the CD33 antigen.
  • CD33 is expressed on leukaemic blasts in over 90% of acute myeloid leukemia (AML) patients.
  • Normal stem cells lack CD33 expression, suggesting targeted toxicity.

Purpose of the Study:

  • To evaluate the efficacy and safety of gemtuzumab ozogamicin in treating acute myeloid leukemia.
  • To assess remission rates and adverse events in adult and pediatric AML patients.

Main Methods:

  • Gemtuzumab ozogamicin administered at 2 doses of 9 mg/m2.
  • Noncomparative studies in adult AML patients in first relapse.
  • Phase I study in children and adolescents with AML.

Related Experiment Videos

Main Results:

  • Complete remission achieved in 16% of adult patients; complete remission with incomplete platelet recovery in an additional 13%.
  • Remission rates were consistent across age groups (under 60 and over 60).
  • Approximately one-third of pediatric patients showed <5% bone marrow blasts post-therapy.

Conclusions:

  • Gemtuzumab ozogamicin demonstrates efficacy in inducing remission in relapsed AML.
  • The drug was generally well-tolerated, with common adverse events including myelosuppression and hepatic enzyme elevation.
  • Outpatient administration was feasible and survival was comparable to hospitalized patients.